Breaking Down Zhejiang Xianju Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

Zhejiang Xianju Pharmaceutical's recent numbers paint a nuanced picture for investors: Q1 2025 revenue surged to ¥1.01 billion-a 32.02% jump from the prior quarter-while full-year 2024 revenue sat at ¥4.00 billion, down 2.98% year-on-year; profitability shows strength with a Q1 2025 gross profit of ¥558.17 million and a gross margin of 55.36%, alongside 2024 net profit of ¥397.18 million (EPS ¥0.40) and ROE of 6.86%; balance-sheet metrics indicate conservative leverage with a debt-to-equity ratio near 20.9%, ample liquidity (current ratio 2.5, quick ratio 1.8, cash ratio 1.2) and solid cash generation (operating cash flow ¥500 million, free cash flow ¥300 million), while valuation sits at a trailing P/E of 34.00 and forward P/E of 15.94 with market cap ¥9.31 billion-set against material risks such as regulatory exposure, raw-material price swings, FX headwinds and competitive pressure and counterbalanced by growth avenues in corticosteroid innovations, overseas expansion and R&D-driven product diversification; explore the full breakdown of revenue segments, margins, liquidity, valuation and risks to decide how these facts shape investment prospects.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) Revenue Analysis

• Q1 2025 revenue: ¥1.01 billion - up 32.02% vs. Q4 2024 (¥763.69 million).
• FY2024 total revenue: ¥4.00 billion - down 2.98% vs. FY2023 (¥4.12 billion).

• Corticosteroids remain the largest revenue contributor (¥2.51B, 2024) and grew modestly (+2.91%).
• Anesthesia & muscle relaxants are a high-growth segment (+43.94%), though from a smaller base (¥252.49M).
• Gynecology & family planning saw a slight decline (¥810.84M, -3.29%), indicating demander shift or pricing pressure.
• International sales contracted to ¥1.04B (-12.04%), weighing on FY2024 total revenue despite strong domestic Q1 2025 performance.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) - Profitability Metrics

Zhejiang Xianju Pharmaceutical's recent profitability picture shows a high product-level margin in Q1 2025 but a moderation in bottom-line metrics year-on-year for 2024. Key headline figures are presented below, followed by a concise analysis of implications for investors.

• Q1 2025 gross profit margin: 55.36% (Gross profit ¥558.17 million on revenue of ¥1.01 billion)
• 2024 net profit attributable to shareholders: ¥397.18 million (EPS ¥0.40)
• 2024 operating profit: ¥678.21 million; 2024 total profit: ¥498.33 million
• 2024 net profit margin: ~9.93% (net profit / total revenue)
• 2024 ROE: 6.86% (net profit / shareholders' equity)
• 2024 EPS: ¥0.40, down from ¥0.57 in prior year

Investor-focused implications - areas to monitor:

• High gross margin in Q1 2025 suggests strong pricing and/or favorable product mix at the cost-of-goods level.
• The gap between robust operating profit (¥678.21M) and lower total profit (¥498.33M) indicates non-operating charges or one-off items reducing pre-tax results.
• Decline in EPS (¥0.40 vs ¥0.57) and moderate ROE (6.86%) point to constrained earnings growth or higher capital base; monitor margin stability and capital efficiency.
• Net profit margin near 10% is reasonable for the sector but needs to be tracked alongside revenue growth to assess sustainability.

For broader context on shareholder composition and investor activity, see: Exploring Zhejiang Xianju Pharmaceutical Co.,Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) - Debt vs. Equity Structure

• Total assets (2023 year-end): ¥6.99 billion
• Total liabilities (2023 year-end): ¥1.16 billion
• Shareholders' equity attributable to listed-company shareholders (2023 year-end): ¥5.79 billion
• Debt-to-equity ratio (2023 year-end): ~20.9% (Total liabilities ÷ Shareholders' equity)
• Approved cash dividend for 2024: ¥0.30 per 10 shares, payable on May 28, 2025
• Q1 2025 interim cash dividend for 2025: ¥0.10 per 10 shares
• Dividend payout ratio for 2024: ~7.5% (based on net profit and total dividends)

• Implication: with liabilities representing roughly one-fifth of equity, the company exhibits low financial leverage and substantial equity buffer.
• Cash-return profile: steady small-per-share dividends (0.30/10 for 2024 and 0.10/10 interim in 2025) consistent with a modest payout ratio (~7.5%).

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) - Liquidity and Solvency

• Current ratio (end‑2023): 2.5 - indicates sufficient short‑term assets to cover current liabilities.
• Quick ratio (end‑2023): 1.8 - strong liquidity excluding inventory.
• Cash ratio (end‑2023): 1.2 - healthy cash buffer versus current liabilities.

• Interest coverage of 5.0 in 2024 suggests comfortable ability to service debt, though not immune to profit volatility.
• Operating cash flow of ¥500M covering 125% of operating expenses signals real cash conversion and operational resilience.
• Free cash flow of ¥300M provides room for debt repayment, dividends, or strategic investments without immediate financing needs.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) Valuation Analysis

• Current price: ¥9.37 (within 52‑week range ¥8.60-¥11.83)
• Market capitalization: ¥9.31 billion
• Shares outstanding: 989.20 million
• Trailing twelve months (TTM) EPS: ¥0.28
• Trailing P/E (as of 2025‑12‑11): 34.00
• Forward P/E: 15.94
• Price‑to‑Sales (P/S): 2.59

• Interpretation: The large gap between trailing P/E (34.00) and forward P/E (15.94) indicates the market is pricing in substantial near‑term earnings improvement or analysts' upward EPS revisions.
• Relative valuation: P/S of 2.59 places the company in a moderate revenue multiple range - investors should compare with sector peers to assess premium or discount.
• Price sensitivity: With EPS of ¥0.28, small absolute EPS changes materially affect P/E; monitor quarterly earnings and guidance for P/E re‑rating risk.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) - Risk Factors

• Regulatory and approval risk: delays or non‑approval of new drugs can defer revenue recognition and R&D capitalization. A single late‑stage approval delay may push expected peak sales out by 1-3 years, reducing NPV of a program by 15-40% depending on discount rate and time to market.
• Raw material and input price volatility: many APIs and excipients are commodity‑sourced. A sustained 10-25% rise in key raw material costs can compress gross margin by ~3-8 percentage points for typical formulation businesses with 30-60% gross margins.
• Exchange‑rate exposure: export sales priced in USD/EUR but reported in RMB expose margins to CNY fluctuations. A 5% depreciation/appreciation in CNY can swing reported international revenue and operating profit by roughly 2-5% depending on the share of exports (e.g., if exports = 20-40% of sales).
• Competitive pressure: generic and branded competition can erode pricing power. Market share losses of 5-15% in key product lines typically translate into 3-10% revenue declines and 2-6 percentage point EBITDA margin contraction absent offsetting cost cuts.
• Healthcare policy & reimbursement changes: adjustments in NRDL (National Reimbursement Drug List) or provincial procurement policies can reduce realized prices; a reimbursement cut of 10-30% on covered products may lower unit revenue and decrease aggregated revenue by 5-20% for companies with concentrated portfolios.
• Quality, recall and reputation risk: a product recall or GMP violation can generate direct costs (recall, remediation) and indirect sales losses. Typical immediate financial impact ranges from tens of millions RMB for localized recalls to hundreds of millions RMB for severe nationwide incidents, plus multi‑year market share recovery timelines.

• Balance sheet and liquidity indicators: watch cash & equivalents, short‑term borrowings and the coverage of interest by operating cash flow. A deterioration where operating cash flow covers <1x of short‑term debt within a rolling 12 months signals rising refinancing and solvency risk.
• Margin sensitivity: model scenarios with ±10-20% revenue and ±10-25% input cost moves; identify break‑even points where EBITDA turns negative or FCF becomes highly constrained.
• Concentration risk: if top 3 products contribute >40-60% of revenue, a single regulatory or reimbursement hit can create outsized volatility in quarterly results.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) Growth Opportunities

• New corticosteroid formulations: the company has announced pipeline additions and scale-up plans-new topical and injectable corticosteroid SKUs could expand addressable market share in dermatology and respiratory segments.
• International expansion: emerging markets in Southeast Asia, Africa and parts of Latin America show above-average pharmaceutical growth (CAGR ~6-9%); targeted registrations and localized partnerships can accelerate export-driven revenue.
• R&D-driven innovation: incremental R&D spending-if maintained at a mid-single-digit percentage of revenue-can produce differentiated, higher-margin specialty generics and formularized products.
• Strategic partnerships: alliances with regional distributors, contract manufacturers and digital health platforms can shorten go-to-market cycles and broaden channel reach.
• Demographic tailwinds: China's aging population increases chronic- and age-related drug demand; market segments relevant to corticosteroids and supportive care are expected to grow faster than GDP.
• Digital health adoption: e-pharmacy, telemedicine integration and digital patient-support programs can raise adherence and average selling prices for chronic therapies while lowering sales & distribution costs.

• R&D spend as % of revenue-sustained reinvestment signals pipeline focus.
• Gross margin by product line-new formulations should show premium or at least stable gross margins versus legacy generics.
• Export revenue growth and receivables days-indicate execution in international markets.
• SG&A per revenue-digital adoption should compress this ratio over time.
• Regulatory milestones and patent/approval timelines-key drivers of value realization.